Engraftment potential of human placenta-derived mesenchymal stem cells after in utero transplantation in rats

Chen, Chie Pein; Liu, Shu Hsiang; Huang, Jian; Aplin, John D.; Wu, Yi-Rui; Chen, Pei Chun; Hu, Cing Siang; Ko, Chun Chuan; Lee, Ming-Yi

doi:10.1093/humrep/den356

Cited by 51 publications

(38 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides the different methods of administration, the timing of delivery and number of cells delivered are also very important. Both higher numbers of MSCs and early phase delivery have been found to improve engraftment rates after the presentation of ischemia [72], and the protocol had been optimized [73].…”

Section: Engraftment Of Mscsmentioning

confidence: 99%

Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair

et al. 2010

View full text Add to dashboard Cite

Section: Engraftment Of Mscsmentioning

confidence: 99%

Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair

et al. 2010

View full text Add to dashboard Cite

“…Thus, human MSCs from several sources have been shown to reconstitute different tissues after human-sheep [9][10][11], human-mouse [12,13], or human-rat [14] xenogeneic in utero transplantation. Furthermore, proof-of-principle studies have recently stressed the therapeutic potential of human fetal MSCs for the treatment of severe osteogenesis imperfecta both after xenogeneic transplantation into the corresponding mouse model [15], and after allogeneic transplantation in an immunocompetent, HLA-incompatible patient [16].…”

Section: Introductionmentioning

confidence: 99%

Fetal Liver-Derived Mesenchymal Stem Cell Engraftment After Allogeneic In Utero Transplantation into Rabbits

Moreno

Martínez-González²,

Rosal³

et al. 2012

Stem Cells and Development

View full text Add to dashboard Cite

Prenatal transplantation of genetically engineered mesenchymal stem cells (MSCs) might benefit prevention or treatment of early-onset genetic disorders due to the cells' intrinsic regenerative potential plus the acquired advantage from therapeutic transgene expression. However, a thorough assessment of the safety, accessibility, and behavior of these MSCs in the fetal environment using appropriate animal models is required before we can advance toward a clinical application. We have recently shown that fetal rabbit liver MSCs (fl-MSCs) have superior growth rate, clonogenic capability, and in vitro adherence and differentiation abilities compared with adult rabbit bone marrow MSCs. In this follow-up study, we report safe and widespread distribution of recombinant pSF-EGFP retrovirus-transduced fl-MSCs (EGFP + -fl-MSCs) in neonatal rabbit tissues at 10 days after fetal allogeneic transplantation through both intrahepatic and intra-amniotic administration. Conversely, a more restricted biodistribution pattern according to the route of administration was apparent in the young rabbits intervened at 16 weeks after fetal EGFP + -fl-MSC transplantation. Furthermore, the presence of these cells in the recipients' tissues, tracked with the reporter provirus, was inversely related to the developmental stage of the fetuses at the time of intervention. Long-term engraftment was confirmed both by fluorescence in situ hybridization analysis on touch tissue imprints using a chromosome Y-specific BAC probe, and by immunohistochemical localization of EGFP expression. Finally, there was no evidence of immune responses against the transplanted EGFP + -fl-MSCs or the EGFP transgenic product in the treated young rabbits. Thus, cell transplantation approaches using genetically engineered fetal MSCs may prove particularly valuable to frontier medical treatments for congenital birth defects in perinatology.

show abstract

“…It was recently demonstrated that fetal membrane MSCs are capable of suppressing proliferation in a mix lymphocyte reaction, decreasing interferon (IFN)-ɣ and interleukin (IL)-17 production, stimulating IL-10 secretion, and increasing levels of adhesion markers CD54, CD29, and CD49d (29). In addition, placenta MSCs are able to engraft and survive long-term in various organs and tissues without evidence of inflammation or rejection after transplantation into neonatal animals and after in utero transplantation into pregnant rats (30,31 Before considering using placenta MSCs for clinical purposes, preclinical studies may be performed and the results must be carefully interpreted in order to assure safety for the patient and success in the therapy. Many preclinical studies on placenta-derived cells and amniotic membrane were reviewed (32), considering a wide range of diseases as neurological, pancreatic, muscle, vascular, cardiac, and pulmonary disorders along with liver fibrosis and applications for tissue engineering.…”

Section: Placenta-derived Stem/progenitor Cellsmentioning

confidence: 99%